002294.SZ
Shenzhen Salubris Pharmaceuticals Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 30.17
−0.85%Oct 26, 2026, 07:50 UTC
Shineway Pharmaceutical reported third-quarter 2026 revenue of 1.264 billion yuan, up 13.81% year over year, and net profit attributable to shareholders of 257 million yuan, up 19.24%.
Source:Oct 8, 2026, 09:45 UTC
Shenzhen Salubris Pharmaceuticals Co., Ltd. reported that it had repurchased 8.3196 million shares, or 0.75% of its current total share capital, for a total of RMB 266 million, excluding transaction fees.
Source:Sep 3, 2026, 11:31 UTC
Shenzhen Salubris Pharmaceuticals updated and resubmitted its H-share listing application to the Hong Kong Stock Exchange on September 3, 2026, for a proposed issuance of overseas listed shares (H shares) and main board listing.
Source:Aug 24, 2026, 10:13 UTC
Shenzhen Salubris Pharmaceuticals reported a net profit of 387.1 million yuan for the first half of 2026.
Aug 14, 2026, 08:43 UTC
Shenzhen Salubris Pharmaceuticals and its wholly-owned subsidiary received an acceptance notice from China's National Medical Products Administration for the clinical trial application of its self-developed Class 1 innovative drug SAL012 injection for treating advanced solid tumors.
Source:Jul 22, 2026, 12:04 UTC
Shenzhen Salubris Pharmaceuticals' new drug application for Sacubitril Valsartan Amlodipine Tablets was accepted for review by China's National Medical Products Administration.
Source: